

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: Final results of a prospective phase II study

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/148028> since

Published version:

DOI:10.1016/j.breast.2014.06.005

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

The Breast, XXX, 2014, 10.1016/j.breast.2014.06.005

The definitive version is available at:

La versione definitiva è disponibile alla URL:

<http://www.sciencedirect.com/science/article/pii/S0960977614001155>

Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: Final results of a prospective phase II study

Luigia Nardone¹, Barbara Diletto¹, Maria Carmen De Santis¹, Giuseppe Roberto D'Agostino¹, Paolo Belli², Enida Bufi², Gianluca Franceschini⁵, Antonio Mulé³, Anna Sapino⁴, Daniela Terribile⁵, Vincenzo Valentini¹

¹*Department of Radiation Oncology, Catholic University of the Sacred Heart, Largo A. Gemelli, 1, 00168 Rome, Italy*

²*Department of Radiology, Catholic University of the Sacred Heart, Largo A. Gemelli, 1, 00168 Rome, Italy*

³*Department of Pathology, Catholic University of the Sacred Heart, Largo A. Gemelli, 1, 00168 Rome, Italy*

⁴*Department of Biomedical Science and Human Oncology, University of Torino, via Santena, 7, 10126 Torino, Italy*

⁵*Department of Surgery, Catholic University of the Sacred Heart, Largo A. Gemelli, 1, 00168 Rome, Italy*

Abstract

Background

To evaluate the efficacy of preoperative low dose fractionated radiotherapy (LD-FRT) and chemotherapy in breast cancer.

Materials and methods

Patients with stage IIA–IIIA breast cancer, received LD-FRT (0.40 Gy bid, on day 1 and 2, for 6 cycles) to primary tumor volume and concurrent chemotherapy with non-pegylated liposomal anthracycline and docetaxel. Pathological response was assessed by Mandard Tumor Regression Grade (TRG). We evaluated the pathological major response rate (PMRR) as TRG1 and TRG2. The expected outcome was a PMRR of 60%. The accrual was determined by the single proportion powered analysis ($\alpha=0.05$, power=0.8).

Results

Twenty-one patients were enrolled. No grade 2–4 acute skin and hematological toxicity was observed. TRG1 was obtained in 3 patients (14.3%), TRG2 in 4 patients (19%). The PMRR was 33.3%; it does not concur with the expected result, but is similar to that of chemotherapy alone. According to molecular subtype, 2/11 *luminal A* patients and 4/6 *luminal B* patients obtained a PMRR to preoperative treatment (35.3%); 1/4 *basal like* patients reported TRG1 (25%).

Conclusions

LD-FRT concomitant with primary systemic treatment has a good toxicity profile. The response rate is consistent with that of chemotherapy alone, and suggests different interactions between low dose radiotherapy and molecular subtypes. Additional investigations are planned.

Keywords

Breast cancer; Low dose radiotherapy; Primary systemic therapy; Preoperative treatment

Introduction

Primary systemic treatment in breast cancer has historically had the aim of reducing unresectable tumors, allowing surgery. For operable tumors, primary chemotherapy could allow a greater rate of breast conservative surgery, reducing the use of mastectomy ¹and ². Moreover the clinical implementation of primary chemotherapy appears to improve disease free survival (DFS) and overall survival (OS) rates in breast cancer ³and ⁴. Primary endpoint of preoperative chemotherapy is the histological tumor response, because it positively correlates with long-term patient survival, and several studies aim to increase the rate of pathological complete response through the association of various chemotherapeutic agents ³, ⁴, ⁵, ⁶, ⁷and ⁸. Over the last 30 years, a broad spectrum of different chemotherapeutic agents has been tested in the preoperative setting. Based upon these results, the respective consensus statements of the 2009 and 2011 St. Gallen Conferences stated that primary systemic treatment regimens should contain an anthracycline and a taxane ⁹and ¹⁰. Anthracycline and taxane-based therapies are widely used in combination or sequential regimens, with pathological tumor response rates ranging between 22% and 31% ¹¹and ¹². While conventional doxorubicin has demonstrated excellent antitumor activity in patients with breast cancer, its clinical utility is limited due to its acute toxicities and the potential for causing cumulative cardiac damage ¹³. An attempt to improve the therapeutic index of anthracyclines, reducing their toxicities, is drug encapsulation in liposomes. We know that liposomal doxorubicin and pegylated liposomal doxorubicin are active in metastatic breast cancer, but several early clinical trials have shown their efficacy and tolerability as primary therapy for locally advanced breast cancer, showing promising results in terms of response rate, which motivate further studies of combined preoperative regimens that incorporate pegylated liposomal doxorubicin ¹⁴.

Preoperative chemotherapy and concomitant radiotherapy have been proposed for different kind of tumors ¹⁵ and ¹⁶. Several studies reported encouraging results about preoperative chemoradiation with taxanes and other chemotherapy regimens for locally advanced breast cancer patients ¹⁷, ¹⁸, ¹⁹and ²⁰. Several cancer cell lines have shown low-dose hyper-radiosensitivity (HRS) at doses <1 Gy; in particular, radiation doses below 0.5 Gy seem to be more effective per unit dose than higher doses. Conversely, an increased radioresistance (IRR) per unit dose to cell killing by radiation has been reported at doses between 0.5 and 1 Gy ²¹, ²² and ²³. *In vitro* data showed that LD-FRT acts as a chemo-potentiator, without increasing toxicity ²⁴. Preliminary results of clinical trials on the association of LD-FRT with chemotherapy suggest the feasibility and effectiveness of this new approach ²⁵, ²⁶, ²⁷ and ²⁸.

In our Institution, we conducted a phase I study, in order to evaluate the feasibility of preoperative LD-FRT in breast cancer, in association with two anthracycline–docetaxel regimens, demonstrating that this new treatment paradigm is feasible and well tolerated, with a toxicity profile similar to that of chemotherapy alone. We obtained a good histological response, with a Tumor Regression Grade (TRG) 1-2 rate of 80% ²⁹. On this setting, we started a single arm phase II study in order to evaluate the efficacy of LD-FRT

and concomitant primary systemic treatment with liposomal anthracycline and docetaxel in terms of pathological response rate and TRG in stage IIA-B and IIIA breast cancer.

Materials and methods

Eligibility criteria were: histological breast cancer diagnosis obtained by core-needle biopsy, no previous treatment, age ≥ 18 , ECOG score 0–2, no evidence of distant metastases, normal hematopoietic, liver, renal and cardiac functions. Patients with c-ErbB2 expression grade 3+, presence of extensive intraductal component, pregnant or in the breastfeeding phase at the time of diagnosis, or with previous or current diagnosis of malignancies other than breast cancer were ineligible.

The study was approved by our institutional review board and by ethics committee. All patients provided a written and informed consent before receiving treatment.

All patients were clinically evaluated by a surgeon and a radiation oncologist. Baseline assessment included a complete clinical examination, mammography, breast ultrasound, breast contrast-enhanced magnetic resonance imaging (MRI), complete cell blood count and serum chemistry, chest and abdomen computed tomography, bone scan, electrocardiogram and cardiac sonography. MRI was performed at baseline, after three cycles of treatment, and before surgery, since patients were part of a diagnostic protocol active in our Institution³⁰. After clinical and radiologic examination, a multidisciplinary team assigned the clinical stage. Tumors were classified according to the International Union Against Cancer TNM 7th edition. Histological grading, hormone receptor status, HER-2-neu expression and Ki-67 rate were evaluated before treatment.

Treatment plan is summarized in Fig.1. Patients were assigned to receive 6 cycles of liposomal anthracycline (50 mg/mq) and docetaxel (75 mg/mq) on day 1 of a 21-day cycle, concurrent with LD-FRT (2 fractions of 0.4 cGy b.i.d on days 1 and 2; total dose 1.6 Gy for 1 cycle). The first RT fraction was delivered before chemotherapy administration, the second fraction was given at least 5–6 h later. The cycle was repeated every 21 days, for a total planned dose of 9.6 Gy (6 cycles, for a total treatment time of 126 days).




Fig.1.
Treatment schedule.

A CT-based planning was used. Patients were scanned in a standard supine position, using a breast board. A radiation oncologist defined the gross tumor volume (GTV), which included the target lesion identified by clinical examination and in pretreatment imaging studies. The clinical target volume (CTV) was obtained adding 10 mm to the GTV, to take into account the suspected subclinical malignant disease; the planning target volume (PTV) was defined as the CTV + 5 mm of margin, to consider internal and set-up errors ³¹. Axillary lymph nodes were not included in the treatment volume, even if clinical or radiological involved.

After 3 weeks from the end of primary systemic treatment, patients underwent clinical and radiological re-examination with mammography, ultrasound and MRI. No clinical and radiological evidence of tumor in the breast and axillary lymph nodes was defined as a clinical Complete Response (cCR). Reduction in total tumor size of 50% or greater was graded as a clinical partial response. Six to eight months after the end of primary chemoradiation treatment, patients underwent breast surgery and axillary node dissection. If breast conservative surgery was not possible, patients were submitted to modified radical mastectomy. Immuno-histochemical evaluation of estrogen and progesterone receptors (ERs, PRs), HER-2-neu and Ki-67 was performed on surgical specimen. We used the molecular subtypes definition recommended by St. Gallen 2013 Consensus ³². Four to six weeks from surgery patients started conventional 3D tangential radiotherapy ± adjuvant chemotherapy ± hormonal therapy, according to prognostic markers and risk factors. Radiation therapy was delivered to the whole breast or to the chest wall, for a total dose of 50.4 Gy. Patients with 4 or more positive axillary nodes received radiotherapy to infraclavicular region and supraclavicular area ³³ and ³⁴. Patients with residual nodes disease (4 or more positive lymph nodes) were submitted to adjuvant chemotherapy.

Primary endpoint of the study was the evaluation of the response rate. Tumor response was defined according to Mandard TRG score ³⁵. TRG1 defines the complete response with the absence of residual cancer and fibrosis extending through the tumor margin; TRG2 describes the presence of residual isolated cells scattered through the fibrosis; TRG3 is the increase in number of residual cancer cells, with fibrosis predominating; TRG4 defines the residual cancer outgrowing the fibrosis; TRG5 describes the absence of regressive changes. TRG1 and TRG2 represent the pathological major response. Tumor response was investigated by a pathologist, and analyzed by an independent and blinded committee of expert pathologists.

Secondary endpoint was the assessment of toxicity. Toxicity was evaluated according to EORTC/RTOG toxicity scale ³⁶. Skin toxicity was recorded after each cycle of LD-FRT and chemotherapy, hematological toxicity was evaluated every week. Preventive granulocyte colony-stimulating factors were administered after each chemotherapy cycle, in order to keep the rate of adverse effects caused by neutropenia and infection low ³⁷ and ³⁸.

The analysis of response proportion was performed by single proportion test and the validation of the accrual was determined by the single proportion powered analysis (Systat 11, SPSS Science, Chicago, IL, USA). We assumed H0 ("bad" response probability) equal

to 30%, according to literature and H1 (“good” response probability) equals to 60%, according to a previous study^{4, 13, 14, 18, 39, 40, 41, 42, 43, 44} and⁴⁵ The number required to detect a difference of 60% versus 30% ($\alpha = 0.05$, power = 0.8) was 21.

Results

Between March 2009 and September 2011, 21 patients with stage IIA-B and IIIA breast cancer were enrolled. The median age was 51 years (range, 32–75). The clinical stage was IIA (cT2N0M0) in 6 patients (28.6%), IIB (cT2N1M0) in 13 patients (61.9%) and IIIA (cT3N1M0- cT3N2M0) in 2 patients (9.5%). The cell type was invasive ductal carcinoma in 18 patients (85.7%) and invasive lobular carcinoma in 3 patients (14.3%). The molecular subtype was *luminal A* in 11 patients (52.4%), *luminal B* in 6 patients (28.6%), *basal like* in 4 patients (19%). Median tumor size, measured as the largest orthogonal diameter on MRI, was 4 cm (range, 1.6–6.7) before preoperative treatment, and 1.7 cm (range, 0–5.0) at the end (Table 1).

Table 1. Patients characteristics.

	N = 21
Age, years	
Range	32–75
Mean	51
Menopausal status	
Premenopausal	10
Postmenopausal	11
Clinical stage	
IIA	6
IIB	13
IIIA	2
Tumor size	
2–5 cm	19
>5 cm	2
Histology	
Invasive ductal cancer	18
Invasive lobular cancer	3
Histologic grade	
G1	1
G2	12

G3	8
Molecular subtypes	
Luminal A	11
Luminal B	6
Triple negative	4

All patients completed the planned treatment: for each patients 6 cycles were administered, for a total dose of LD-FRT of 9.6 Gy. Patient compliance to treatment was good. The pathological response was classified as TRG1 in 3 patients (14.3%), TRG2 in 4 patients (19%), TRG3-5 in 14 patients (66.6%). The pathological major response rate (PMRR: TRG1 and TRG2) obtained was 33.3%. These results were analyzed by an independent and blinded committed, who found four minor conflicts for TRG 3-5 patients; no conflicts were found for other patients, especially for TRG 1-2 patients. A detailed description of tumor response according to clinical and pathological stage is reported in Table2.

Table 2. Tumor response according to clinical and pathological stage.

!Fine imprevista della formula	Clinical Staging cTNM	Tumor size (cm) in RM prior LDFRT and CT	Tumor size (cm) in RM post LDFRT and CT	Ki 67 rate prior LDFRT and CT (%)	Pathological staging ypTNM	Ki 67 rate post LDFRT and CT (%)	Molecular subtype	TRG	TRG revision by external committee
1	T3N1M0	5.5	1.5	25	T1mN1a	7	Luminal B	TRG3	TRG3
2	T2N0M0	4.2	0	3	T1micN1micM0	70	Luminal A	TRG1	TRG1
3	T2N1M0	4.0	0	80	T0N0M0	–	Triple neg	TRG1	TRG1
4	T2N1M0	2.5	2.5	30	T1micN2aM0	1	Luminal B	TRG2	TRG2
5	T3N1M0	6.7	5.0	45	T2N3aM0	20	Luminal B	TRG4	TRG4
6	T2N0M0	2.9	2.9	90	T1aN0M0	90	Triple neg	TRG4	TRG5
7	T2mN1M0	3.5	2.2	1	T1micN1aM0	1	Luminal A	TRG2	TRG2
8	T2N1M0	3.2	1.0	40	T1bN2aM0	25	Luminal B	TRG3	TRG4
9	T2N1M0	4.4	4.4	15	T2N1aM0	12	Luminal A	TRG4	TRG4
10	T2N1M0	3.4	3.4	25	T2N1aM0	20	Luminal B	TRG5	TRG5
11	T2N0M0	3.0	0.4	80	T1aN0M0	3	Luminal B	TRG2	TRG2

!Fine imprevista della formula	Clinical Staging cTNM	Tumor size (cm) in RM prior LDFRT and CT	Tumor size (cm) in RM post LDFRT and CT	Ki 67 rate prior LDFRT and CT (%)	Pathological staging ypTNM	Ki 67 rate post LDFRT and CT (%)	Molecular subtype	TRG	TRG revision by external committee
12	T2N1M0	3.0	0	35	T0N0M0	–	Luminal B	TRG2	TRG2
13	T2N1M0	5.0	5.0	20	T2N0M0	20	Luminal B	TRG5	TRG5
14	T2N1M0	3.0	1.7	45	T2N3aM0	70	Luminal B	TRG4	TRG4
15	T2N1M0	3.0	1.5	12	T2N2aM0	5	Luminal A	TRG3	TRG3
16	T2N0M0	3.2	1.5	3	T1cN0M0	3	Luminal A	TRG3	TRG4
17	T2N1M0	3.5	2.7	70	T2N0M0	90	Triple neg	TRG4	TRG5
18	T2N1M0	2.2	3.1	70	T2N0M0	90	Triple Neg	TRG4	TRG4
19	T2N0M0	2.7	1.6	12	T1cN0M0	4	Luminal A	TRG3	TRG3
20	T2N0M0	2.3	1.7	25	T1cN0M0	8	Luminal B	TRG3	TRG3
21	T2N0M0	4	0	70	T0N0M0	–	Luminal B	TRG1	TRG1

There were no grade 2–4 hematological events. Grade 1 hematologic toxicity was observed in 6 patients (anemia and leuco-neutropenia). There were no severe infections due to neutropenia. Most common non-hematological toxicities reported were nausea, diarrhea and alopecia, which occurred in all patients. Grade 1 acute skin toxicity was observed in 1 patient. No acute skin toxicity \geq grade 2 was reported. There were no cardiac events.

All patients underwent surgery: 18 patients (85.7%) had quadrantectomy, 3 (14.3%) patients were submitted to mastectomy with breast reconstruction. We did not observe any postoperative complications. Adjuvant radiotherapy was delivered to the whole breast in 18 patients; infra and supraclavicular irradiation was administered to 6 patients with \geq 4 positive lymph nodes. After surgery and radiotherapy, 4 patients with residual nodal disease were assigned to receive adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil for 6 cycles. Five patients with hormonal receptors positive, received tamoxifen and LH–RH analogue, 3 patients received only tamoxifen and 8 patients aromatase inhibitors.

Median follow-up was 31 months. At the time of analysis all patients were alive, 2 patients had distant metastasis at 4,8 and 1,3 months from diagnosis, respectively.

Discussion

Primary systemic treatment is the standard for management of stage IIA-IIB/IIIA breast cancer. Primary aim is the achievement of a pCR, which is correlated to a better 10-year OS and DFS and a lower risk of recurrences^{3, 4} and⁵. A wide variety of chemotherapy regimens have been used as preoperative treatment, with most incorporating doxorubicin. These regimens generally determine a response rate in at least two-thirds of patients with a complete pathological remission rate of roughly 10–15%⁴. Anthracyclines, such as doxorubicin, are considered among the most active single agents in advanced breast cancer. However, the use of anthracyclines is limited by their acute toxicities and by their cumulative cardiac damage. An attempt to improve the therapeutic index of anthracyclines includes drug encapsulation in liposomes. The encapsulation of a cytostatic agent within a vector such as a liposome, significantly reduces its diffusion and consequently the toxicity for healthy tissue, while increasing the concentration within the tumor. Several clinical trials evaluated the effectiveness of nonpegylated and pegylated liposomal anthracyclines and have shown them to have similar efficacy with less cardiac toxicity when compared with free doxorubicin^{46, 47} and⁴⁸. Radiotherapy involving the heart region is one of the possible risk factors for anthracycline cardiotoxicity, so in an effort to prevent or reduce this effect liposomal anthracyclines has been administered in our trial. Taxanes are strongly active in breast cancer treatment. Concomitant use of docetaxel and anthracyclines led to a clinical overall response rates of 77–96%, and to a breast conservation rate of 89%^{7, 49} and⁵⁰. There are only few experience about the concomitant administration of taxanes and radiotherapy in breast cancer, proving the safety and the efficacy of this association⁵¹.

The role of preoperative radiotherapy in breast cancer treatment, sequential or concomitant to chemotherapy, has been explored in some studies. Formenti and colleagues examined the role of primary concurrent paclitaxel and radiotherapy for patients with locally advanced breast cancer; they obtained a pCR in 16% of patients, with a marked grade 3 skin toxicity and a high rate of surgical complications (14%)¹⁹. In a subsequent study they reported that pathologic response to concurrent paclitaxel-radiation translated into superior DFS and OS, and that half of the patients with hormonal receptor negative tumors achieved a pathologic response^{17, 18, 19} and²⁰. Administration of LD-FRT to the primary tumor, instead of standard fractionation to the whole breast, concomitant with chemotherapy in preoperative setting could reduce acute skin toxicity and post-surgical complications.

Several preclinical and clinical studies have proved the HRS phenomenon at low dose of radiotherapy and the chemo-sensitizing effect of LD-FRT^{21, 22, 23, 24, 25, 26, 27, 28} and²⁹. Mammalian cells exhibit HRS to radiation doses less than 0.3–0.6 Gy^{21, 22} and⁵². HRS does not activate cellular repair mechanisms, often observed at clinically relevant or higher radiation doses, and thus could explain why there is no induction of radiation resistance with HRS as measured *in vitro*²¹. Furthermore, HRS failed to induce prosurvival transcription factors, that are necessary for increasing the levels of MDR-1 gene⁵³. Hence, no MDR-1 induction in response to LD-FRT will help to increase the effects of chemotherapy, that is often mitigated by MDR-1⁵⁴. The use of LD-FRT with chemotherapy provides a new strategy to improve tumor downstaging through the use of radiotherapy as

a biological modifier of the chemotherapy response. Combined chemo-radiotherapy strategies to enrich the G2-phase fraction before radiotherapy obtained promising results in experimental setting. LD-FRT has been combined with cell synchronization using taxanes to radiosensitize squamous cell carcinoma of head and neck in nude mice tumor xenografts: low doses of radiation (0.1–0.6 Gy) were found to induce HRS phenomenon, and doses more than 1Gy demonstrated IRR⁵⁵ and⁵⁶. These data supported the use of LD-FRT as a chemopotentiator in several investigative clinical trials. A phase I trial reported that LD-FRT to the upper abdomen was well tolerated at 0.6 Gy per fraction when combined with gemcitabine in patients with pancreatic cancer⁵⁷. In patients with locally advanced head and neck cancer LD-FRT were used as induction therapy in a pilot trial, in combination with carboplatin and taxol, with good results in terms of response rate and toxicity profile.²⁵ In our Institution several experiences has been conducted with LD-FRT and concomitant chemotherapy. Concurrent palliative chemotherapy and LD-FRT have been evaluated in patients with various type of epithelial tumors; the overall response rate was 45% with low toxicity²⁶. A prospective phase II study demonstrated that LD-FRT combined with pemetrexed in patients affected by recurrent non small cell lung cancer is a feasible and well tolerated novel approach, with a response rate of 42%²⁷. A phase I study reported that concomitant LD-FRT and chemotherapy with non-pegylated liposomal anthracycline and docetaxel is a feasible preoperative approach in treatment of IIA-B/IIIA stage breast cancer. The skin and hematological toxicity profile was very low, and we not observed cardiac toxicity or postsurgical complications; the PMRR obtained was 80%²⁹. Considering these results we started a single arm phase II study in order to evaluate the efficacy of this new primary treatment approach.

The expected pathological major response rate of 60% was not achieved, but the obtained result of 33.3% was consistent with that of chemotherapy alone (pCR, 23–29%)³⁹ and⁴⁰. Several early clinical trials have shown the efficacy and tolerability of liposomal doxorubicin and pegylated liposomal doxorubicin as primary systemic treatment in association with paclitaxel or docetaxel for locally advanced breast cancer^{41, 42, 43, 44} and⁴⁵. They all obtained good results in terms of response rate, with a pCR rate of 7–16%, that is similar to that reported by our trial. It should be noted that in our trial we considered both TRG1 and TRG2 as a pathological major response (33.3%), on the basis of clinical and histopathological findings: our pathologist and the independent committee agreed about the observation that LD-FRT induces a greater fibrotic reaction than chemotherapy alone, which encases the residual tumor. This finding is supported by the evidence that LD-FRT could have an effect also on the inflammatory cellular components of tumors, by decreasing the number of cells, reducing the tumor-associated interstitial edema, and modifying the biochemical microenvironment, which support the tumor growth⁵⁸.

A recent metanalysis provides evidence of an independent association between breast cancer molecular subtype and pCR, observing that *basal like* patients are more responsive to chemotherapy (pCR 31.1%) than *luminal A-B* patients (pCR 8.3%)⁵⁹. In our study *luminal A-B* patients obtained a pathological major response rate higher then *basal like* subtype (35.3% versus 25%), suggesting a possible mechanism of interaction of LD-FRT with different molecular subtypes. However the low statistical power, due to the small

sample size of the study, cannot reliably rule out the importance of these biomarkers in terms of pathological response.

No evidence was found that LD-FRT increases the rate of radiation-induced toxicity; we did not observe cardiotoxicity, pneumonitis and serious skin reactions. For local failure rates, late toxicity and cosmetic outcome longer follow-up is needed.

Our results demonstrated that the combination of LD-FRT and chemotherapy with liposomal anthracycline and docetaxel is well tolerated, with a toxicity profile similar to chemotherapy alone. Nevertheless the expected increase of response has not been observed, so further research steps are directed towards increasing the number of patients with different molecular subtypes, in order to provide results that may change practice in chemoresistant breast cancer subtypes.

Conclusions

Results of this phase II study demonstrated that preoperative low dose radiotherapy and concomitant chemotherapy with non-pegylated liposomal doxorubicin and docetaxel have a low toxicity profile. The pathological major response rate obtained on primary tumor is similar to that of chemotherapy alone, and suggests different interactions of low dose radiotherapy with various breast cancer molecular subtypes. Additional investigations are warranted.

Conflict of interest statement

All authors declare no conflict of interest.

Funding statement

There is no funding supporting the research.

Ethical approval

The study was approved by ethics committee.

References

1. E. Touboul, L. Buffat, J.P. Lefranc, J. Blondon, E. Deniaud, H. Mammar, *et al.* *Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer* Int J Radiat Oncol Biol Phys, 34 (5) (1996 Mar 15), pp. 1019–1028
2. G. Calais, C. Berger, P. Descamps, S. Chapet, A. Reynaud-Bougnoux, G. Body, *et al.* *Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm* Cancer, 74 (4) (1994 Aug 15), pp. 1283–1288

3. M.A. Mouret-Reynier, C. Abrial, M. Leheurteur, X. Durando, I. Van Praagh, P. Gimbergues, *et al. Indications, contra-indications, expected results and choice of neoadjuvant chemotherapy for operable breast cancer* Bull Cancer, 93 (11) (Nov 1 2006), pp. 1121–1129
4. M.J. Piccart, J. Kerger, E. Tomiak, D.J. Perrault, *Systemic treatment for locally advanced breast cancer: what we still need to learn after a decade of multimodality clinical trials* Eur J Cancer, 28 (2–3) (1992), pp. 667–672
5. P. Rastogi, S.J. Anderson, H.D. Bear, C.E. Geyer, M.S. Kahlenberg, A. Robidoux, *et al. Preoperative chemotherapy: update of national surgical adjuvant breast and bowel project B-18 and B-27* J Clin Oncol, 26 (2008), pp. 778–785
6. Specht, J.R. Gralow *Neoadjuvant chemotherapy for locally advanced breast cancer* Semin Radiat Oncol, 19 (2008), pp. 222–228
7. W.F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, *et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy* J Clin Oncol, 25 (28) (2007 Oct 1), pp. 4414–4422
8. S.C. Abrial, F. Penault-Llorca, R. Delva, P. Bougnoux, B. Leduc, M.A. Mouret-Reynier, *et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer* Breast Cancer Res Treat, 94 (3) (2005 Dec), pp. 255–263
9. Goldhirsch, J.N. Ingle, R.D. Gelber, A.S. Coates, B. Thürlimann, H.J. Senn Panel members. *Thresholds for therapies: highlights of the St Gallen International Expert consensus on the primary therapy of early breast cancer* 2009 Ann Oncol, 20 (8) (2009 Aug), pp. 1319–1329
10. Goldhirsch, W.C. Wood, A.S. Coates, R.D. Gelber, B. Thürlimann, H.J. Senn Panel members. *Strategies for subtypes dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer* 2011 Ann Oncol, 22 (8) (2011 Aug), pp. 1736–1747
11. Kai, N. Arima, H. Miyayama, Y. Yamamoto, H. Iwase, R. Nishimura *Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study* Breast Cancer, 16 (1) (2009), pp. 42–48
12. Sachelarie, M.L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, R.H. Blum *Primary systemic therapy of breast cancer* Oncologist, 11 (6) (2006 Jun), pp. 574–589
13. G.N. Hortobágyi *Anthracyclines in the treatment of cancer* Overv Drugs, 54 (Suppl. 4) (1997), pp. 1–7
14. Campos *Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer* Oncologist, 8 (Suppl. 2) (2003), pp. 10–16

15. J.R. Bellon, K.L. Lindsley, G.K. Ellis, J.R. Gralow, R.B. Livingston, M.M. Austin Seymour
16. *Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer* Int J Radiat Oncol Biol Phys, 48 (2) (2000 Sep 1), pp. 393–397
17. K.A. Mason, N.R. Hunter, M. Milas, J.L. Abbruzzese *Docetaxel enhances tumor radioresponse in vivo* Clin Cancer Res, 3 (1997), pp. 2431–2438
18. K.A. Skinner, H. Silberman, B. Florentine, T.J. Lomis, F. Corso, D. Spicer, et al. *Preoperative paclitaxel and radiotherapy for locally advanced breast cancer: surgical aspects* Ann Surg Oncol, 7 (2) (2000 Mar), pp. 145–149
19. A.B. Chakravarthy, M.C. Kelley, B. McLaren, C.I. Truica, D. Billheimer, I.A. Mayer, et al. *Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer* Clin Cancer Res, 12 (5) (2006), pp. 1570–1576
20. Adams, A.B. Chakravarthy, M. Donach, D. Spicer, S. Lymberis, B. Singh, et al. *Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival* Breast Cancer Res Treat, 124 (3) (2010 Dec), pp. 723–732
21. S.C. Formenti, M. Volm, K.A. Skinner, D. Spicer, D. Cohen, E. Perez, et al. *Pre-operative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial* J Clin Oncol, 21 (2003), pp. 864–870
22. M.C. Joiner, B. Marples, P. Lambin, S.C. Short, I. Turesson *Low-dose hypersensitivity: current status and possible mechanisms* Int J Radiat Oncol Biol Phys, 49 (2) (2001 Feb 1), pp. 379–389
23. Marples, P. Lambin, K.A. Skov, M.C. Joiner *Low dose hyperradiosensitivity and increased radioresistance in mammalian cells* Int J Radiat Oncol Biol Phys, 71 (1997), pp. 721–735
24. L.M. Martin, B. Marples, T.H. Lynch, D. Hollywood, L. Marignol *Exposure to low dose ionising radiation: molecular and clinical consequences* Cancer Lett, 338 (2) (2013 Sep 28), pp. 209–218
25. Chendil, R. Oakes, R.A. Alcock, N. Patel, C. Mayhew, M. Mohiuddin, et al. *Low-dose fractionated radiation enhances the radio-sensitization effect of paclitaxel in colorectal tumour cells with mutant p53* Cancer, 89 (2000), pp. 1893–1900
26. S.M. Arnold, W.F. Regine, M.M. Ahmed, J. Valentino, P. Spring, M. Kudrimoti, et al. *Low dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm* Int J Radiat Oncol Biol Phys, 58 (2004), pp. 1411–1417

27. V. Valentini, M. Massaccesi, M. Balducci, G. Mantini, F. Micciché, G.C. Mattiucci, *et al.* *Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings?* *Int J Radiat Oncol Biol Phys*, 76 (2010), pp. 535–539
28. G. Mantini, V. Valentini, B. Meduri, S. Margaritora, M. Balducci, F. Micciché, *et al.* *Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study* *Radiother Oncol*, 105 (2) (2012 Nov), pp. 161–166
29. M. Balducci, S. Chiesa, B. Diletto, G.R. D'Agostino, A. Mangiola, S. Manfreda, *et al.* *Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study* *Neuro Oncol*, 14 (1) (2012 Jan), pp. 79–86
30. L. Nardone, V. Valentini, L. Marino, M.C. De Santis, D. Terribile, G. Franceschini, *et al.* *A feasibility study of neo-adjuvant low-dose fractionated radiotherapy with two different oncurrent anthracycline-docetaxel schedules in stage IIA/B-IIIA breast cancer* *Tumori*, 98 (2012), pp. 79–85
31. Bufi, P. Belli, M. Costantini, P. Rinaldi, M. Di Matteo, A. Bonatesta, *et al.* *MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer* *Br J Radiol*, 85 (1019) (2012 Nov), pp. e995–1103
32. A.M. Kirby, C.E. Coles, J.R. Yarnold *Target volume definition for external beam partial breast radiotherapy: clinical, pathological and technical studies informing current approaches* *Radiother Oncol*, 94 (3) (2010 Mar), pp. 255–263
33. Goldhirsch, E.P. Winer, A.S. Coates, R.D. Gelber, M. Piccart-Gebhart, B. Thürlimann, *et al.* *Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013* *Ann Oncol*, 24 (9) (2013 Sep), pp. 2206–2223
34. T.J. Whelan, J. Julian, J. Wrigth, A.R. Jadad, M.L. Levine *Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis* *J Clin Oncol*, 13 (2000), pp. 1220–1229
35. H. Bartelink, J.C. Horiot, P. Poortmans, H. Struikmans, W. Van den Bogaert, I. Barillot, *et al.* *Recurrence rate after treatment of breast cancer with standard radiotherapy with or without additional radiotherapy* *N Engl J Med*, 345 (2001), pp. 378–1387
36. A.M. Mandard, F. Dalibard, J.C. Mandard *Pathologic assessment of tumor regression grade after pre-operative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations* *Cancer*, 73 (1994), pp. 2680–2686
37. J.D. Cox, J. Stetz, T.F. Pajak *Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of cancer (EORTC)* *Int J Radiat Biol*, 30 (1995), pp. 1341–1346

38. G.G. Steger, A. Galid, M. Gnant, B. Mlineritsch, A. Lang, C. Tausch, *et al.* ABCSG-14. *Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14* J Clin Oncol, 25 (15) (2007 May 20), pp. 2012–2018
39. P. Renner, S. Milazzo, J.P. Liu, M. Zwahlen, J. Birkmann, M. Horneber *Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients* Cochrane Database Syst Rev, 10 (2012 Oct 17) CD007913
40. L. Gianni, J. Baselga, W. Eiermann, V.G. Porta, V. Semiglazov, A. Lluch, *et al.* *Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer* J Clin Oncol, 27 (15) (2009 May 20), pp. 2474–2481
41. G. Von Minckwitz, G. Raab, A. Caputo, M. Schütte, J. Hilfrich, J.U. Blohmer, *et al.* *Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPAR DUO study of the German Breast Group* J Clin Oncol, 23 (12) (2005 Apr 20), pp. 2676–2685
42. P. Schmid, J. Krocker, C.O. Schulz, K. Michniewicz, A. Dieing, H. Eggemann, *et al.* *Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial* Anticancer Drugs, 16 (1) (2005 Jan), pp. 21–29
43. H. Gogas, C. Papadimitriou, H.P. Kalofonos, D. Bafaloukos, G. Fountzilas, D. Tsavdaridis, *et al.* *Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group* Ann Oncol, 13 (11) (2002 Nov), pp. 1737–1742
44. Rossi, A.M. Baldelli, V. Casadei, S.L. Fedeli, P. Alessandrini, V. Catalano, *et al.* *Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer* Anticancer Drugs, 19 (7) (2008 Aug), pp. 733–737
45. R. Torrì, E. Montagna, E. Scarano, S. Dellapasqua, G. Canello, M. Iorfida, *et al.* *Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluorouracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer* Breast, 20 (1) (2011 Feb), pp. 34–38
46. Artioli, S. Mocellin, L. Borgato, A. Cappetta, F. Bozza, G. Zavagno, *et al.* *Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer* Anticancer Res, 30 (9) (2010 Sep), pp. 3817–3821

47. L. Harris, G. Batist, R. Belt, D. Rovira, R. Navari, N. Azarnia, *et al.* *Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma* *Cancer*, 94 (1) (2002 Jan 1), pp. 25–36
48. M.E. O'Brien, N. Wigler, M. Inbar, R. Rosso, E. Grischke, A. Santoro, *et al.* *CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer* *Ann Oncol*, 15 (3) (2004 Mar), pp. 440–449
49. Batist, G. Ramakrishnan, C.S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, *et al.* *Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer* *J Clin Oncol*, 19 (5) (2001 Mar 1), pp. 1444–1454
50. J.R. Gralow, H.J. Burstein, W. Wood, G.N. Hortobagyi, L. Gianni, G. von Minckwitz, *et al.* *Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease* *J Clin Oncol*, 26 (2008), pp. 814–819
51. M. Kaufmann, G. von Minckwitz, H.D. Bear, A. Buzdar, P. McGale, H. Bonnefoi, *et al.* *Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006* *Ann Oncol*, 18 (2007), pp. 1927–1934
52. K. Karasawa, K. Katsui, K. Seki, M. Kohno, N. Hanyu, S. Nasu, *et al.* *Radiotherapy with concurrent docetaxel for advanced and recurrent breast cancer* *Breast Cancer*, 10 (2003), pp. 268–274
53. B. Marples, J. Spencer, S.J. Collis *Low-dose hyper-radiosensitivity: past, present, and future* *Int J Radiat Oncol Biol Phys*, 70 (2008), pp. 1310–1318
54. M.M. Shareef, B. Brown, S. Shajahan, S. Sathishkumar, S.M. Arnold, M. Mohiuddin, *et al.* *Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF- κ B activation in oral carcinoma cells* *Mol Cancer Res*, 6 (2008), pp. 89–98
55. S. Gupta, T. Koru-Sengul, S.M. Arnold, G.R. Devi, M. Mohiuddin, M.M. Ahmed *Low-dose fractionated radiation potentiates the effects of cisplatin independent of the hyper-radiation sensitivity in human lung cancer cells* *Mol Cancer Ther*, 10 (2) (2011 Feb), pp. 292–302
56. P.M. Spring, S.M. Arnold, S. Shajahan, *et al.* *Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck* *Cell Cycle*, 3 (4) (2004 Apr), pp. 479–485

57. S. Dey, P.M. Spring, S. Arnold, *et al.* *Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines* Clin Cancer Res, 9 (4) (2003 Apr), pp. 1557–1565
58. W.F. Regine, N. Hanna, M.C. Garofalo, S. Sathishkumar, S.M. Arnold, M. Mohiuddin, *et al.* *Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm* Int J Radiat Oncol Biol Phys, 68 (1) (2007 May 1), pp. 172–177
59. F. Rödel, B. Frey, G. Capalbo, U. Gaipl, L. Keilholz, R. Voll, *et al.* *Discontinuous induction of X-linked inhibitor of apoptosis in EA.hy.926 endothelial cells is linked to NF- κ B activation and mediates the anti-inflammatory properties of low-dose ionising-radiation* Radiother Oncol, 97 (2) (2010 Nov), pp. 346–351
60. N. Houssami, P. Macaskill, G. von Minckwitz, M.L. Marinovich, E. Mamounas *Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy* Eur J Cancer, 48 (18) (2012 Dec), pp. 3342–3354

Corresponding author. Tel.+39 0630155339; fax: +39 0630155908.